RemeGen Co., Ltd. (REGMF)
REGMF Stock Price Chart
Explore RemeGen Co., Ltd. interactive price chart. Choose custom timeframes to analyze REGMF price movements and trends.
REGMF Company Profile
Discover essential business fundamentals and corporate details for RemeGen Co., Ltd. (REGMF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Jan 2021
Employees
3.00K
Website
https://www.remegen.comCEO
Jianmin Fang
Description
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
REGMF Financial Timeline
Browse a chronological timeline of RemeGen Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Mar 2026
Upcoming earnings on 25 Mar 2026
Upcoming earnings on 27 Oct 2025
Earnings released on 22 Aug 2025
Revenue for the quarter reached $79.82M .
Earnings released on 28 Apr 2025
EPS came in at -$0.06 , while revenue for the quarter reached $72.46M .
Earnings released on 27 Mar 2025
EPS came in at -$0.06 , while revenue for the quarter reached $69.10M , beating expectations by +12.36%.
Earnings released on 29 Oct 2024
EPS came in at -$0.08 , while revenue for the quarter reached $66.57M , missing expectations by -0.58%.
Earnings released on 16 Aug 2024
EPS came in at -$0.11 , while revenue for the quarter reached $56.60M , beating expectations by +9.43%.
Earnings released on 26 Apr 2024
EPS came in at -$0.09 , while revenue for the quarter reached $45.75M , beating expectations by +3.26%.
Earnings released on 27 Mar 2024
EPS came in at -$0.13 , while revenue for the quarter reached $44.26M , missing expectations by -6.89%.
Earnings released on 30 Sept 2023
EPS came in at -$0.08 , while revenue for the quarter reached $47.96M .
Earnings released on 30 Jun 2023
EPS came in at -$0.10 , while revenue for the quarter reached $35.08M .
Earnings released on 31 Mar 2023
EPS came in at -$0.09 , while revenue for the quarter reached $24.47M .
Earnings released on 27 Feb 2023
EPS came in at -$0.08 , while revenue for the quarter reached $29.57M , missing expectations by -0.93%.
Earnings released on 27 Oct 2022
EPS came in at -$0.05 , while revenue for the quarter reached $30.69M .
Earnings released on 30 Aug 2022
EPS came in at -$0.06 , while revenue for the quarter reached $29.88M .
Earnings released on 27 Apr 2022
EPS came in at -$0.09 , while revenue for the quarter reached $23.63M .
Earnings released on 16 Mar 2022
EPS came in at -$0.08 , while revenue for the quarter reached $13.22M .
Earnings released on 31 Dec 2021
EPS came in at $0.31 , while revenue for the quarter reached $205.61M .
Earnings released on 30 Jun 2021
EPS came in at -$0.08 , while revenue for the quarter reached $3.85M .
Earnings released on 31 Mar 2021
EPS came in at -$0.06 , while revenue for the quarter reached $652.13K .
Earnings released on 31 Dec 2020
EPS came in at -$0.07 .
Earnings released on 30 Sept 2020
EPS came in at -$0.07 .
REGMF Stock Performance
Access detailed REGMF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.